Abstract

BackgroundWe aimed to evaluate the frequency of various types of B and T cells expressing CD21, CD32, and CD35 in multiple sclerosis (MS) clinical courses.MethodsPeripheral blood mononuclear cell from 30 MS patients (17 relapsing remitting [RRMS], six secondary progressive [SPMS], and seven primary progressive MS [PPMS]) and 18 healthy subjects were analyzed. All patients were in acute attack. Healthy controls were matched for age and gender ratio. The frequencies of various subsets of B and T cells were determined using flow cytometry.ResultsThe frequency of CD4+T cells was lower in MS patients compared to control subjects (41.14 ± 9.45% vs. 46.88 ± 6.98%, respectively, P < 0.05). The CD32+ fraction of CD4+T cells and the CD21+ fraction of CD8+T cells were higher in MS patients (2.85 ± 3.72% vs. 1.06 ± 0.62% for CD32+CD4+T cells, 2.71 ± 1.86% vs. 1.16 ± 0.99% for CD21+CD8+T cells in MS patients and control subjects, respectively, P < 0.05). After dividing subjects by type of MS course, higher values of these two T cell subsets were found in SPMS patients compared to control subjects (P < 0.05). Further, RRMS patients had lower levels of CD32+CD4+T cells than SPMS patients and also they had lower levels of CD32+CD8+T cells than PPMS patients (P < 0.05). However, neither the expression of CD35 on T cells nor the various B cell subsets were statistically different between the compared groups.ConclusionsOur findings demonstrate that T cell subsets expressing CD21 and CD32 may differ with respect to the presence or clinical forms of MS disease. By contrast, CD35+T cells and different subsets of B cells are not altered in various MS clinical courses.

Highlights

  • We aimed to evaluate the frequency of various types of B and T cells expressing CD21, CD32, and CD35 in multiple sclerosis (MS) clinical courses

  • We found that CD21, CD32 and CD35 markers are more likely to be detected on CD19+ B cells than on CD4+ or CD8+ T cells

  • We found that the expression of CD32 on both CD4+ and CD8+ T cells is altered in progressive courses of MS in comparison to Relapsing remitting multiple sclerosis (RRMS)

Read more

Summary

Introduction

We aimed to evaluate the frequency of various types of B and T cells expressing CD21, CD32, and CD35 in multiple sclerosis (MS) clinical courses. Multiple Sclerosis (MS) is a chronic autoimmune demyelinating disease, which imposes huge burden on quality of life and socioeconomic status of patients [1,2,3]. MS manifests itself in various clinical forms (e.g. relapsing remitting MS [RRMS], secondary progressive MS [SPMS], and primary progressive MS [PPMS]) and its course in each individual is varied and unpredictable [1,4]. CD161 expression on CD8+ T cells may contribute to the MS pathogenesis [9] In this respect, other subsets of B and T cells (e.g. CD29+, CD44+, and CD45RA+) have been evaluated in MS patients [10,11,12]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call